July 3, 2024
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the proposed merger between the below listed companies.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of the company being acquired.  

Kuehn Law is investigating whether the Board of Directors of the target company:

1) acted to maximize shareholder value,
2) failed to disclose material information, and
3) conducted a fair process:  
Agile Therapeutics, Inc. has agreed to be acquired by Insud Pharma, S.L. Under the terms of the agreement, Agile shareholders will receive $1.52 per Agile share in cash.